{"kind":"expression","expression":{"expr_id":"330","doc_id":"330","label":"2017 Revision","is_as_enacted":"f","commenced_on":null,"superseded_on":null,"valid_from":null,"valid_to":null,"is_current":"t","incorporating":null,"akn_expr_iri":"\/akn\/ky\/act\/sl\/1981\/22\/eng@2017-01-01","akn_envelope":"{\"_canary\": {\"iri\": {\"work\": \"\/akn\/ky\/act\/sl\/1981\/22\", \"expression\": \"\/akn\/ky\/act\/sl\/1981\/22\/eng@2017-01-01\", \"manifestation\": \"\/akn\/ky\/act\/sl\/1981\/22\/eng@2017-01-01.pdf\"}, \"pdf\": {\"md5\": \"3149da298b24dbf924b66080464d8c09\", \"path\": \"\/Users\/q\/kyleg-data\/working\/SUBORDINATE\/1981\/1981-0022\/1981-0022_2017 Revision.pdf\", \"pages\": 15, \"filename\": \"1981-0022_2017 Revision.pdf\"}, \"errors\": [], \"extraction\": {\"model\": null, \"stats\": {\"word_count\": 1514, \"paragraph_count\": 4, \"text_char_count\": 12396}, \"usage\": null, \"method\": \"pymupdf-text\", \"version\": \"kyleg-akn-1.0\", \"extracted_at\": \"2026-06-22\"}, \"classification\": \"text_layer\", \"validation_flags\": [], \"docai_processor_id\": null}, \"akomaNtoso\": {\"act\": {\"body\": [{\"eId\": \"sec_n1\", \"num\": null, \"text\": \"Pharmacy Law, 1979 PHARMACY (POISONS AND RESTRICTED PHARMACEUTICALS) REGULATIONS (2017 Revision) PUBLISHING DETAILS The Pharmacy (Poisons and Restricted Pharmaceuticals) Regulations, 1981 made the 8th December, 1981consolidated with the Pharmacy (Poisons and Restricted Pharmaceuticals) (Amendment) Regulations, 2016 made the 9th August, 2016. Revised under the authority of the Law Revision Law (1999 Revision). Consolidated and revised this 1st day of  May,  2017. Note ( note forming part of the Regulations): This revision replaces the 1999 Revision which should now be discarded. Arrangement of Regulations Pharmacy Law, 1979 PHARMACY (POISONS AND RESTRICTED PHARMACEUTICALS) REGULATIONS (2017 Revision) Arrangement of Regulations Regulation 1. 2.\", \"element\": \"section\", \"heading\": null}, {\"eId\": \"sec_3\", \"num\": \"3.\", \"text\": \"SCHEDULE 1 Poisons SCHEDULE 2 Restricted Pharmaceuticals Regulation 1 Pharmacy Law, 1979 PHARMACY (POISONS AND RESTRICTED PHARMACEUTICALS) REGULATIONS (2017 Revision)\", \"element\": \"section\", \"heading\": null}, {\"eId\": \"sec_1\", \"num\": \"1.\", \"text\": \"Citation 1. These Regulations may be cited as the Pharmacy (Poisons and Restricted Pharmaceuticals) Regulations (2017 Revision).\", \"element\": \"section\", \"heading\": null}, {\"eId\": \"sec_2\", \"num\": \"2.\", \"text\": \"Poisons 2. The chemical substances prescribed in Schedule 1 hereto are poisons for the purposes of the Law. 3. Restricted pharmaceuticals 3. The pharmaceuticals prescribed in Schedule 2 hereto are restricted pharmaceuticals for the purposes of the Law. SCHEDULE 1 SCHEDULE 1 regulation 2 Poisons Aldrin Arsensical substances Arsenious oxide Arsenic sulphides Calcium arsenates Calcium arsenites Copper acetoarsenite Copper arsenates Copper arsenites Lead arsenates Sodium arsenates Sodium thioarsanates Sodium arsenites Barium carbonate Dieldrin Dinitrocresols (DNOC): their compounds with a metal or a base Dinosam; its compound with a metal or a base. SCHEDULE 2 SCHEDULE 2 regulation 3 Restricted Pharmaceuticals Part I Acetanilide: alkyl acetanilides Acetohoexamide Acetylcarbronal Allylisopropylacetylurea Barbituric acid; its salts; derivatives of barbituric acid; their salts; compound of barbituric acid; its salts; its derivatives; their salts with any other substance Busulphan; its salts Cannabis extracts and tinctures of cannabis Demecarium bromide Digitalis and related substances or compounds Dinitrocresols (DNOC), their compounds with a metal or a base Dinitronaphthols; dinitrophenols; dinitrothynols Disulfuram Dithienylallylamines, dithienylalkylamines; their salts, except diethylthiambutene, dimethylthiambutene and ethylmethylthiambutene Fentanyl; its salts Gallamine; its salts; its quaternary compounds Mannomustine; its salts Mercaptopurine; its salts Mustine; and any N-substituted derivatives of di (2-cholorethyl) amine; their salts Phenacemide Phenylcinchoninic acid: salicylcinchoninic acid; their salts; their esters Polymethylenebistrimethylammonium salts Tretamine; its salts Tri-(1-aziridinyl)-1, 4 benzoquinone Amidopyrine; its salts; amidopyrine sulphonates; their salts-p-Aminobenzenesulphonamide; its salts, derivatives of paminobenzenesulphonamide having any of the hydrogen atoms of the p-amino group or of the sulphonamide group substituted by another radical; their salts, except when contained in ointments or surgical dressings or in preparations for the prevention and treatment of diseases in poultry. SCHEDULE 2 B-Aminopropylbenzene and B-aminoispropylbenzene and any compound structurally derived from either of those substances by substitutions in the side chain or by ring closure therein (or by both such substitutions and closure), except ephedrine, Nmethylephedrine, N-Diethylamineothylephedrine, phenylopropanolamine and prenalymine; any salt of any substance falling within this item Amitriptyline and other antidepressant compounds Androgenic, oestrogenic and progestational substances, the following- Benzoestrol Derivatives of stilbene, dibenzyl or naphthalene with oestrogenic activity; their esters Steroid compounds with androgenic or oestrogenic or progestational activity; their esters Azacyclonol; its salts Benactyzine; its salts Benzhexol; its salts Benztropine and its homologues; their salts Bronvaletone Captodiame; its salts Cabromal Carisoprodol Chloral; its addition and its condensation products; their molecular compounds Chlordiazepoxide; its salts 2-p-Chlorophynyl-3-Methylbutane-2; 3 diol Chlorothiazide and other derivatives of benzo-1,2,4 -thiadiazine-7 sulphonamide 1, 1dioxide, whether hydrogenated or not Chlorphentermine; its salts Chlorphenoxamine Chlorpropamide; its salts Chlorprothixene Chlorthalidone Cyclarbamate Cycrimine (l-cyclopentyl-1-1-phenyl-3 piperidinopropran-0-01); its salts Desipramine; its salts Diazepam and related compounds Diphenoxlate and its salts contained in (a) pharmaceutical preparations in solid or liquid form containing not more than 2.5 millg. of diphenoxylate calculated as base and not less than 25 microgrammes of atropine calculated as atropine sulphate per dosage unit or (b) liquid preparation containing 0.5 milligrammes diphenoxylate hydrochloride, 0.005 millg. atropine sulphate, 0.16 millilitres ethyl alcohol, 0.002 millilitres imitation cherry flavour, 0.45 millilitres glycerine, 0.4 millilitres sorbital solution (70 per cent), 0.01 SCHEDULE 2 milligrammes red dye colour index No. 14700 (F.D. 4C. Red No. 4), 0.008 millilitres water. Ectylurea Emylcamate Ethchlorvynol Ethinamate Ethopheptazine; its salts Glutethimide; its salts Haloperidol Hexapropymate Hydrazines, benzyl phenethyl of phenoxy-ethyl; their a-methyl derivatives; acyl derivatives of any of the foregoing substances comprised in this item; salts of any compounds comprised in this item 4-hydroxymethyl-2, 2-disopropyl 1-1, 3-dioxalan Hydroxyzine; its salts Imipramine; its salts Mephenesin; its esters Meprobamate Metaxalone Metformin; its salts Methaqualone; its salts Methixene; its salts Methocarbamol Methosxalen Methylpentynol; its esters and other derivatives Methylprylone Modecate (Fluphenazine Decanoate) and related substances or compounds Nortryptyline; its salts Orphenadrine; its salts Oxethazaine Oxyphenbutazone and related compounds Paramethadione Pargyline; its salts Pemoline; its salts Phenaglycodol SCHEDULE 2 Phenbutrazate Phenetidylphenacetin Phenformin; its salts Phenothiazine, derivatives of: their salts, except dimethozanate, its salts and premethazine, its salts and molecular compounds Phenylbutezone; its salts 5-Phenylhydantoin; its alkyl and aryl derivatives; their salts Pituitary gland, the active principals of: except when containing preparation intended for external application only, or except in case of Lysinevasopressin or oxytocin, in inhalants Procyclidine; its salts Propranolol and related compounds Prothipendyl; its salts Quinethazone Rauwolfia, alkaloids of: their salts, derivates of the alkaloids of rauwolfia; their salts Styramate Sulphimpyrazone Sulphonal; alky sulphonals Suprarenal gland medulla, the active principles of; their salts except when contained in preparations intended for external application only or in inhalants, rectal preparations or preparations intended for use in the eye Syrosingopine Tetrabenazine; its salts Thyroid gland, the active principles of: their salts Tolbutamide Tribromethyl alcohol Trimipramine; its salts Troxidone Zoxazolamine; its salts 2,2,2 Trichloroethyl alcohol, esters of: their salts Part II Morphine and its salts, and any solution or dilution of morphine or its salts in an inert substance whether liquid or solid containing any proportion of morphine, and any preparation, admixture, extract or other substance (not being such solution or dilution as aforesaid) containing not less than one-fifth of one per cent morphine (calculated in respect of anhydrous morphine) SCHEDULE 2 Cocaine (including synthetic cocaine) and ecgonine and their respective salts, and any solution or dilution of cocaine or its salts in an inert substance, whether liquid or solid, containing any proportion of cocaine, and any preparation, admixture, extract or other substance (not being such a solution or dilution as aforesaid) containing not less than onetenth of one per cent of cocaine or any proportion of ecgonine Acetyldihydrocodeinone Alphaprodine Alphameprodine Benzylmorphine Betameprodine Betaprodine Diethylthiambutene Dioxaphetyl butyrate (4-morpholino-2: 2-diphenyl ethyl butyrate) Didipanone Ethylmethylthiambutene Hydrocodone (also known as dihydrocodeinone or dicodide) Hyrdomorphone (also known as dihydromorphinone or dilaudide) Hydroxypethidine Isomethadone (also known as isoamidone) Ketobemidone Levomethorphan Levorphanol Methadol Methadone (also known as amidone) Methadyl acetate Methyldesomorphine (6-methyl-6-desoxymorphine) 1-Methyl-4-phenylpiperidine-4- carboxylic acid isopropyl ester Metopon (also known as methyldihydromorphinone) Morphine-N-oxide (also known as genormorphine) Normethadone Omnopon Osycodone (also known as dihydrohydroxcodeinone or eucodal) Pethidine (Demerol) Phenzdoxone Phenomorphan (3-hydroxy-N-phenethylmorphinan) SCHEDULE 2 Propoxyphene Racemethorphan Racemorphan Thebaine The esters of morphine (other than diacetylmorphine), ecogonine, Oxycodone, hydrocodone, hydromorphone, acetyldihydrocodeinone and dihydromorphine; the ethers of morphine (other than benzylmorphine, codeine, ethylmorphine and pholcodine); the morphine-N-oxide derivatives and any other pentavalent nitrogen morphine derivatives. Part III Amphotericin B Bacitracin Cephaloridine Cefoxitin Chloramphenicol Chloramphenicol and its salts Colistin Sulphate Cycloserine Erythromycin Framycetin Griseofulvin Kanamycin sulphate Lincomycin hydrochloride Neomycin Novobiocin Nystatin Paromomycin sulphate Penicillin G Benzyl penicillin sodium or potassium salt Procaine penicillin Fortified procaine, penicillin and other long-acting preparations Benzathine penicillin Phenoxymethyl penicillin Penicillin V, free base or potassium salt or calcium salt Phenbenicillin Phenoxybenzyl penicillin SCHEDULE 2 Phenethicillin potassium Cloxacillin sodium Methicillin sodium Ampicillin Polymyxin- B- sulphate Ristocetin Spectinomycin Spiramycin Streptomycin sulphate Streptomycin penicillin mixtures Dihydrostreptomycin Sulphomyxin sodium Tetracyclines Chlortetracycline Oxytetracyline Tetracycline Demethylchlortetracyline Lymecycline Methacycline Triacetyloleandomycin Tyrothricin Vancomycin Viomycin pantothenate and sulphate Viomycin sulphate All other antibiotics and chemotherapeutic agents. Part IV Chenopodium Oil Coumarin Dinitrobenzene Lysergic Acid Diethylamide Tetrahydrocannabinoe SCHEDULE 2 Publication in revised form authorised by the Cabinet this 22nd day of May, 2017. Clerk of  Cabinet\", \"element\": \"section\", \"heading\": null}], \"meta\": {\"notes\": null, \"workflow\": null, \"lifecycle\": {\"source\": \"#cilegis\", \"eventRef\": [{\"eId\": \"e_commence_2017_01_01\", \"date\": \"2017-01-01\", \"type\": \"generation\", \"source\": \"#cilegis\"}]}, \"references\": {\"source\": \"#canary\", \"TLCRole\": [], \"TLCEvent\": [{\"eId\": \"ev_commencement\", \"href\": \"\/akn\/ontology\/canary\/event\/commencement\", \"showAs\": \"commencement\"}], \"TLCPerson\": [], \"TLCConcept\": [{\"eId\": \"inForce\", \"href\": \"\/akn\/ontology\/canary\/concept\/temporal\/in-force\", \"showAs\": \"in force\"}], \"TLCProcess\": [], \"TLCLocation\": [], \"TLCOrganization\": [{\"eId\": \"cilegis\", \"href\": \"\/akn\/ontology\/canary\/organization\/editor\/cilegis\", \"showAs\": \"Cayman Islands legislation mirror (kyleg)\"}]}, \"temporalData\": {\"source\": \"#cilegis\", \"temporalGroup\": [{\"eId\": \"tg_inforce_2017_01_01\", \"timeInterval\": [{\"end\": null, \"start\": \"#e_commence_2017_01_01\", \"duration\": null, \"refersTo\": \"#inForce\"}]}]}, \"classification\": null, \"identification\": {\"source\": \"#cilegis\", \"FRBRWork\": {\"FRBRuri\": \"\/akn\/ky\/act\/sl\/1981\/22\", \"FRBRdate\": [{\"date\": \"2017-01-01\", \"name\": \"generation\"}], \"FRBRthis\": \"\/akn\/ky\/act\/sl\/1981\/22\/!main\", \"FRBRalias\": [{\"name\": \"cmsId\", \"value\": \"1981-0022\"}], \"FRBRauthor\": [{\"as\": \"#editor\", \"href\": \"\/akn\/ontology\/canary\/organization\/editor\/cilegis\"}], \"FRBRnumber\": \"22 of 1981\", \"FRBRcountry\": \"ky\", \"FRBRsubtype\": \"subordinate\"}, \"FRBRExpression\": {\"FRBRuri\": \"\/akn\/ky\/act\/sl\/1981\/22\/eng@2017-01-01\", \"FRBRdate\": [{\"date\": \"2017-01-01\", \"name\": \"generation\"}], \"FRBRthis\": \"\/akn\/ky\/act\/sl\/1981\/22\/eng@2017-01-01\/!main\", \"FRBRauthor\": [{\"as\": \"#editor\", \"href\": \"\/akn\/ontology\/canary\/organization\/editor\/cilegis\"}], \"FRBRlanguage\": \"eng\"}, \"FRBRManifestation\": {\"FRBRuri\": \"\/akn\/ky\/act\/sl\/1981\/22\/eng@2017-01-01.xml\", \"FRBRdate\": [{\"date\": \"2026-06-22\", \"name\": \"generation\"}], \"FRBRthis\": \"\/akn\/ky\/act\/sl\/1981\/22\/eng@2017-01-01.xml\", \"FRBRauthor\": [{\"as\": \"#editor\", \"href\": \"\/akn\/ontology\/canary\/organization\/editor\/cilegis\"}], \"FRBRformat\": \"application\/xml\"}}}, \"name\": \"act\", \"header\": {\"title\": \"Pharmacy (Poisons and Restricted Pharmaceuticals) Regulations\", \"actNumber\": \"22 of 1981\", \"longTitle\": null}}, \"doc\": null, \"bill\": null, \"judgment\": null}}","akn_full_text":"CAYMAN ISLANDS\n\nPharmacy Law, 1979\nPHARMACY (POISONS AND\nRESTRICTED PHARMACEUTICALS)\nREGULATIONS\n\n(2017 Revision)\nSupplement No. 24 published with Extraordinary Gazette No. 45 of 31st May, 2017.\n\nPage 2\nRevised as at 1st day of  May,  2017\nc\n\nPUBLISHING DETAILS\nThe Pharmacy (Poisons and Restricted Pharmaceuticals) Regulations, 1981 made the 8th\nDecember, 1981consolidated with the Pharmacy (Poisons and Restricted\nPharmaceuticals) (Amendment) Regulations, 2016 made the 9th August, 2016.\nRevised under the authority of the Law Revision Law (1999 Revision).\nConsolidated and revised this 1st day of  May,  2017.\nNote ( note forming part of the Regulations): This revision replaces the 1999 Revision\nwhich should now be discarded.\n\nPharmacy (Poisons and Restricted Pharmaceuticals) Regulations\nArrangement of Regulations\n\nc\nRevised as at 1st day of  May,  2017\nPage 3\n\nCAYMAN ISLANDS\n\nPharmacy Law, 1979\nPHARMACY (POISONS AND RESTRICTED\nPHARMACEUTICALS) REGULATIONS\n(2017 Revision)\nArrangement of Regulations\nRegulation\nPage\n1.\nCitation ......................................................................................................................................5\n2.\nPoisons......................................................................................................................................5\n3.\nRestricted pharmaceuticals ........................................................................................................5\nSCHEDULE 1\n7\nPoisons\n7\nSCHEDULE 2\n8\nRestricted Pharmaceuticals\n8\n\nPharmacy (Poisons and Restricted Pharmaceuticals) Regulations\nRegulation 1\n\nc\nRevised as at 1st day of  May,  2017\nPage 5\n\nCAYMAN ISLANDS\n\nPharmacy Law, 1979\nPHARMACY (POISONS AND RESTRICTED\nPHARMACEUTICALS) REGULATIONS\n(2017 Revision)\n\n1.\nCitation\n1.\nThese Regulations may be cited as the Pharmacy (Poisons and Restricted\nPharmaceuticals) Regulations (2017 Revision).\n2.\nPoisons\n2.\nThe chemical substances prescribed in Schedule 1 hereto are poisons for the\npurposes of the Law.\n3.\nRestricted pharmaceuticals\n3.\nThe pharmaceuticals prescribed in Schedule 2 hereto are restricted pharmaceuticals\nfor the purposes of the Law.\n\nPharmacy (Poisons and Restricted Pharmaceuticals) Regulations\nSCHEDULE 1\n\nc\nRevised as at 1st day of  May,  2017\nPage 7\n\n SCHEDULE 1\nregulation 2\nPoisons\nAldrin\nArsensical substances\nArsenious oxide\nArsenic sulphides\nCalcium arsenates\nCalcium arsenites\nCopper acetoarsenite\nCopper arsenates\nCopper arsenites\nLead arsenates\nSodium arsenates\nSodium thioarsanates\nSodium arsenites\nBarium carbonate\nDieldrin\nDinitrocresols (DNOC): their compounds with a metal or a base\nDinosam; its compound with a metal or a base.\n\nSCHEDULE 2\nPharmacy (Poisons and Restricted Pharmaceuticals) Regulations\n\nPage 8\nRevised as at 1st day of  May,  2017\nc\n\nSCHEDULE 2\nregulation 3\nRestricted Pharmaceuticals\nPart I\nAcetanilide: alkyl acetanilides\nAcetohoexamide\nAcetylcarbronal\nAllylisopropylacetylurea\nBarbituric acid; its salts; derivatives of barbituric acid; their salts; compound of barbituric\nacid; its salts; its derivatives; their salts with any other substance\nBusulphan; its salts\nCannabis extracts and tinctures of cannabis\nDemecarium bromide\nDigitalis and related substances or compounds\nDinitrocresols (DNOC), their compounds with a metal or a base\nDinitronaphthols; dinitrophenols; dinitrothynols\nDisulfuram\nDithienylallylamines, dithienylalkylamines; their salts, except diethylthiambutene,\ndimethylthiambutene and ethylmethylthiambutene\nFentanyl; its salts\nGallamine; its salts; its quaternary compounds\nMannomustine; its salts\nMercaptopurine; its salts\nMustine; and any N-substituted derivatives of di (2-cholorethyl) amine; their salts\nPhenacemide\nPhenylcinchoninic acid: salicylcinchoninic acid; their salts; their esters\nPolymethylenebistrimethylammonium salts\nTretamine; its salts\nTri-(1-aziridinyl)-1, 4 benzoquinone\nAmidopyrine;\nits\nsalts;\namidopyrine\nsulphonates;\ntheir\nsalts-p-Aminobenzenesulphonamide; its salts, derivatives of paminobenzenesulphonamide having any of\nthe hydrogen atoms of the p-amino group or of the sulphonamide group substituted by\nanother radical; their salts, except when contained in ointments or surgical dressings or in\npreparations for the prevention and treatment of diseases in poultry.\n\nPharmacy (Poisons and Restricted Pharmaceuticals) Regulations\nSCHEDULE 2\n\nc\nRevised as at 1st day of  May,  2017\nPage 9\n\nB-Aminopropylbenzene and B-aminoispropylbenzene and any compound structurally\nderived from either of those substances by substitutions in the side chain or by ring\nclosure therein (or by both such substitutions and closure), except ephedrine, Nmethylephedrine,\nN-Diethylamineothylephedrine,\nphenylopropanolamine\nand\nprenalymine; any salt of any substance falling within this item\nAmitriptyline and other antidepressant compounds\nAndrogenic, oestrogenic and progestational substances, the following- Benzoestrol\nDerivatives of stilbene, dibenzyl or naphthalene with oestrogenic activity; their esters\nSteroid compounds with androgenic or oestrogenic or progestational activity; their esters\nAzacyclonol; its salts\nBenactyzine; its salts\nBenzhexol; its salts\nBenztropine and its homologues; their salts\nBronvaletone\nCaptodiame; its salts\nCabromal\nCarisoprodol\nChloral; its addition and its condensation products; their molecular compounds\nChlordiazepoxide; its salts\n2-p-Chlorophynyl-3-Methylbutane-2; 3 diol\nChlorothiazide and other derivatives of benzo-1,2,4 -thiadiazine-7 sulphonamide 1, 1dioxide, whether hydrogenated or not\nChlorphentermine; its salts\nChlorphenoxamine\nChlorpropamide; its salts\nChlorprothixene\nChlorthalidone\nCyclarbamate\nCycrimine (l-cyclopentyl-1-1-phenyl-3 piperidinopropran-0-01); its salts\nDesipramine; its salts\nDiazepam and related compounds\nDiphenoxlate and its salts contained in (a) pharmaceutical preparations in solid or liquid\nform containing not more than 2.5 millg. of diphenoxylate calculated as base and not less\nthan 25 microgrammes of atropine calculated as atropine sulphate per dosage unit or (b)\nliquid preparation containing 0.5 milligrammes diphenoxylate hydrochloride, 0.005\nmillg. atropine sulphate, 0.16 millilitres ethyl alcohol, 0.002 millilitres imitation cherry\nflavour, 0.45 millilitres glycerine, 0.4 millilitres sorbital solution (70 per cent), 0.01\n\nSCHEDULE 2\nPharmacy (Poisons and Restricted Pharmaceuticals) Regulations\n\nPage 10\nRevised as at 1st day of  May,  2017\nc\n\nmilligrammes red dye colour index No. 14700 (F.D. 4C. Red No. 4), 0.008 millilitres\nwater.\nEctylurea\nEmylcamate\nEthchlorvynol\nEthinamate\nEthopheptazine; its salts\nGlutethimide; its salts\nHaloperidol\nHexapropymate\nHydrazines, benzyl phenethyl of phenoxy-ethyl; their a-methyl derivatives; acyl\nderivatives of any of the foregoing substances comprised in this item; salts of any\ncompounds comprised in this item\n4-hydroxymethyl-2, 2-disopropyl 1-1, 3-dioxalan\nHydroxyzine; its salts\nImipramine; its salts\nMephenesin; its esters\nMeprobamate\nMetaxalone\nMetformin; its salts\nMethaqualone; its salts\nMethixene; its salts\nMethocarbamol\nMethosxalen\nMethylpentynol; its esters and other derivatives\nMethylprylone\nModecate (Fluphenazine Decanoate) and related substances or compounds Nortryptyline;\nits salts\nOrphenadrine; its salts\nOxethazaine\nOxyphenbutazone and related compounds\nParamethadione\nPargyline; its salts\nPemoline; its salts\nPhenaglycodol\n\nPharmacy (Poisons and Restricted Pharmaceuticals) Regulations\nSCHEDULE 2\n\nc\nRevised as at 1st day of  May,  2017\nPage 11\n\nPhenbutrazate\nPhenetidylphenacetin\nPhenformin; its salts\nPhenothiazine, derivatives of: their salts, except dimethozanate, its salts and\npremethazine, its salts and molecular compounds\nPhenylbutezone; its salts\n5-Phenylhydantoin; its alkyl and aryl derivatives; their salts\nPituitary gland, the active principals of: except when containing preparation intended for\nexternal application only, or except in case of Lysinevasopressin or oxytocin, in inhalants\nProcyclidine; its salts\nPropranolol and related compounds\nProthipendyl; its salts\nQuinethazone\nRauwolfia, alkaloids of: their salts, derivates of the alkaloids of rauwolfia; their salts\nStyramate\nSulphimpyrazone\nSulphonal; alky sulphonals\nSuprarenal gland medulla, the active principles of; their salts except when contained in\npreparations intended for external application only or in inhalants, rectal preparations or\npreparations intended for use in the eye\nSyrosingopine\nTetrabenazine; its salts\nThyroid gland, the active principles of: their salts\nTolbutamide\nTribromethyl alcohol\nTrimipramine; its salts\nTroxidone\nZoxazolamine; its salts\n2,2,2 Trichloroethyl alcohol, esters of: their salts\nPart II\nMorphine and its salts, and any solution or dilution of morphine or its salts in an inert\nsubstance whether liquid or solid containing any proportion of morphine, and any\npreparation, admixture, extract or other substance (not being such solution or dilution as\naforesaid) containing not less than one-fifth of one per cent morphine (calculated in\nrespect of anhydrous morphine)\n\nSCHEDULE 2\nPharmacy (Poisons and Restricted Pharmaceuticals) Regulations\n\nPage 12\nRevised as at 1st day of  May,  2017\nc\n\nCocaine (including synthetic cocaine) and ecgonine and their respective salts, and any\nsolution or dilution of cocaine or its salts in an inert substance, whether liquid or solid,\ncontaining any proportion of cocaine, and any preparation, admixture, extract or other\nsubstance (not being such a solution or dilution as aforesaid) containing not less than onetenth of one per cent of cocaine or any proportion of ecgonine\nAcetyldihydrocodeinone\nAlphaprodine\nAlphameprodine\nBenzylmorphine\nBetameprodine\nBetaprodine\nDiethylthiambutene\nDioxaphetyl butyrate (4-morpholino-2: 2-diphenyl ethyl butyrate)\nDidipanone\nEthylmethylthiambutene\nHydrocodone (also known as dihydrocodeinone or dicodide)\nHyrdomorphone (also known as dihydromorphinone or dilaudide)\nHydroxypethidine\nIsomethadone (also known as isoamidone)\nKetobemidone\nLevomethorphan\nLevorphanol\nMethadol\nMethadone (also known as amidone)\nMethadyl acetate\nMethyldesomorphine (6-methyl-6-desoxymorphine)\n1-Methyl-4-phenylpiperidine-4- carboxylic acid isopropyl ester\nMetopon (also known as methyldihydromorphinone)\nMorphine-N-oxide (also known as genormorphine)\nNormethadone\nOmnopon\nOsycodone (also known as dihydrohydroxcodeinone or eucodal)\nPethidine (Demerol)\nPhenzdoxone\nPhenomorphan (3-hydroxy-N-phenethylmorphinan)\n\nPharmacy (Poisons and Restricted Pharmaceuticals) Regulations\nSCHEDULE 2\n\nc\nRevised as at 1st day of  May,  2017\nPage 13\n\nPropoxyphene\nRacemethorphan\nRacemorphan\nThebaine\nThe esters of morphine (other than diacetylmorphine), ecogonine, Oxycodone,\nhydrocodone, hydromorphone, acetyldihydrocodeinone and dihydromorphine; the ethers\nof morphine (other than benzylmorphine, codeine, ethylmorphine and pholcodine); the\nmorphine-N-oxide derivatives and any other pentavalent nitrogen morphine derivatives.\nPart III\nAmphotericin B\nBacitracin\nCephaloridine\nCefoxitin\nChloramphenicol\nChloramphenicol and its salts\nColistin Sulphate\nCycloserine\nErythromycin\nFramycetin\nGriseofulvin\nKanamycin sulphate\nLincomycin hydrochloride\nNeomycin\nNovobiocin\nNystatin\nParomomycin sulphate\nPenicillin G\nBenzyl penicillin sodium or potassium salt\nProcaine penicillin\nFortified procaine, penicillin and other long-acting preparations\nBenzathine penicillin\nPhenoxymethyl penicillin\nPenicillin V, free base or potassium salt or calcium salt\nPhenbenicillin\nPhenoxybenzyl penicillin\n\nSCHEDULE 2\nPharmacy (Poisons and Restricted Pharmaceuticals) Regulations\n\nPage 14\nRevised as at 1st day of  May,  2017\nc\n\nPhenethicillin potassium\nCloxacillin sodium\nMethicillin sodium\nAmpicillin\nPolymyxin- B- sulphate\nRistocetin\nSpectinomycin\nSpiramycin\nStreptomycin sulphate\nStreptomycin penicillin mixtures\nDihydrostreptomycin\nSulphomyxin sodium\nTetracyclines\nChlortetracycline\nOxytetracyline\nTetracycline\nDemethylchlortetracyline\nLymecycline\nMethacycline\nTriacetyloleandomycin\nTyrothricin\nVancomycin\nViomycin pantothenate and sulphate\nViomycin sulphate\nAll other antibiotics and chemotherapeutic agents.\nPart IV\nChenopodium Oil\nCoumarin\nDinitrobenzene\nLysergic Acid\nDiethylamide\nTetrahydrocannabinoe\n\nPharmacy (Poisons and Restricted Pharmaceuticals) Regulations\nSCHEDULE 2\n\nc\nRevised as at 1st day of  May,  2017\nPage 15\n\nPublication in revised form authorised by the Cabinet this 22nd day of May, 2017.\nClerk of  Cabinet","akn_extracted_at":"2026-06-22 15:39:31.565483+00","cms_id":"1981-0022","law_type":"subordinate","year":"1981","number":"22","title":"Pharmacy (Poisons and Restricted Pharmaceuticals) Regulations","status":"in_force"},"provenance":{"files":[{"file_id":"5235","expr_id":"330","kind":"akn_xml","filename":"1981-0022_2017 Revision.akn.xml","source_url":null,"storage_path":"\/Users\/q\/kyleg-data\/working\/SUBORDINATE\/1981\/1981-0022\/1981-0022_2017 Revision.akn.xml","content_md5":"86d79cb81ebc94a2b466816c26bd15c9","byte_size":"13512","http_last_modified":null,"fetched_at":"2026-06-22 15:39:31.625292+00"},{"file_id":"659","expr_id":"330","kind":"pristine_pdf","filename":"1981-0022_2017 Revision.pdf","source_url":"\/cms\/images\/LEGISLATION\/SUBORDINATE\/1981\/1981-0022\/1981-0022_2017 Revision.pdf","storage_path":"\/Users\/q\/kyleg-data\/pristine\/SUBORDINATE\/1981\/1981-0022\/1981-0022_2017 Revision.pdf","content_md5":"3149da298b24dbf924b66080464d8c09","byte_size":"298209","http_last_modified":null,"fetched_at":"2026-06-21 23:09:37.622115+00"},{"file_id":"660","expr_id":"330","kind":"working_pdf","filename":"1981-0022_2017 Revision.pdf","source_url":"\/cms\/images\/LEGISLATION\/SUBORDINATE\/1981\/1981-0022\/1981-0022_2017 Revision.pdf","storage_path":"\/Users\/q\/kyleg-data\/working\/SUBORDINATE\/1981\/1981-0022\/1981-0022_2017 Revision.pdf","content_md5":"3149da298b24dbf924b66080464d8c09","byte_size":"298209","http_last_modified":null,"fetched_at":"2026-06-21 23:09:37.622115+00"}],"paragraph_count":16,"latest_history":null},"quality":{"expr_id":"330","doc_id":"330","quality_state":"needs_review","quality_score":"84","needs_human_review":"t","deterministic_categories":"{duplicate_text,page_header_footer_noise}","llm_categories":"{truncated_text,other}","repair_actions":"{collapse_duplicate_text,manual_review,reextract_full_text,strip_page_furniture}","finding_severity_counts":"{\"low\": 1, \"medium\": 1}","finding_summary":"Sample shows likely truncation at end of Schedule\u202f2; review completeness and remove any non\u2011regulatory closing statements if they are not part of the law.","assessed_at":"2026-06-22 15:29:45.96333+00","updated_at":"2026-06-22 15:29:45.96333+00"}}